Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00308087

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00308087. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.

Study identification

NCT ID: NCT00308087
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genzyme, a Sanofi Company; Industry
Enrollment: 75 participants

Conditions and interventions

Conditions

Lymphoma, Follicular

Interventions

Sargramostim (Leukine) Drug
Rituximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2006 (Type not available)
Primary completion: Jun 2009 (Actual)
Completion: Jun 2009 (Actual)
Last update posted: Dec 27, 2013

2006 – 2009

United States locations

U.S. sites: 21
U.S. states: 10
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35234	—
Not listed	Huntsville	Alabama	35805	—
Not listed	Los Angeles	California	90095	—
Not listed	Montebello	California	90640	—
Not listed	Pleasant Hill	California	94523	—
Not listed	Gainesville	Florida	32610-0254	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Ocala	Florida	34474	—
Not listed	Tampa	Florida	33612	—
Not listed	Chicago	Illinois	60612	—
Not listed	Elk Grove Village	Illinois	60007	—
Not listed	Springfield	Illinois	62703	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	New Albany	Indiana	47150	—
Not listed	Duluth	Minnesota	55805-1984	—
Not listed	Fresh Meadows	New York	11365	—
Not listed	New York	New York	10019	—
Not listed	Columbus	Ohio	43235	—
Not listed	Hershey	Pennsylvania	17033-0850	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00308087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 27, 2013 · Synced Nov 14, 2026